Click to Enlarge
Facebook
Twitter
The Financial Times has a spot for the Alzheimer’s drug too, focusing on the trial results released by US pharmaceutical group Eli Lilly. The company has submitted donanemab for approval by the US Food and Drug Administration and expects a decision this year, according to the paper. In other news, under a headline reading “Losing pace”, there is a report about China’s economy growing by “just 0.8%” – the business paper predicts this could “pile pressure on global growth”.

Financial Times Front Page 24th of July 2024

Ministers may need to put Britain’s high-speed rail plans on hold as a result of significant cost overruns and delays, highlighting broader economic challenges and budgetary constraints, compounded by warnings about the NHS reaching a critical point and potential future reductions in transport capacity.

Read More »